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Background: The purpose of this study was to evaluate retrospectively the clinical performance of the Bicarbon
valve (Sorin Biomedica Cardio, Saluggia, Italy) implanted at our center in Japan.
Methods: Between January 1997 and December 2011, 415 patients in our institution were implanted with the
Bicarbon valve. Nine of these recipients were excluded from the study because they had already undergone
valve implantation and received a Bicarbon valve in a different position. The remaining patients were analyzed
for evaluation of the postoperative clinical outcomes. Of the 406 patients (mean age 60.2 ± 11.7 years), 179
underwent aortic valve replacement (AVR), 149 mitral valve replacement (MVR), and 78 both aortic and
mitral valve replacement (DVR).
Results: There were 10 early deaths (2.5 %: 4 in the AVR group and 6 in the MVR group). Three hundred
eighty-nine patients were followed up (95.8 % completeness of follow-up) with a mean follow-up of 6.6 ± 4.2
years overall (AVR 6.8 ± 4.2, MVR, 6.7 ± 4.4, and DVR 5.7 ± 3.4 years) and a cumulative follow-up of 2661
patient-years (1214, 1001, and 446 patient-years for AVR, MVR, and DVR, respectively). Ninety-nine patients
died (3.7 % per patient-year: 22 valve-related and 77 valve-unrelated deaths). Survival at 10 years was 74.1 ± 4.0 %
in the AVR group, 73.7 ± 4.2 % in the MVR group, and 61.0 ± 7.9 % in the DVR group. The linearized incidence of
thromboembolic complications, bleeding complications, prosthetic valve endocarditis, paravalvular leaks, and
sudden death in all patients was 0.5 %, 0.5 %, 0.2 %, 0.2 %, and 0.4 % per patient-year, respectively. The incidence of
valve-related complications and reoperation was 1.6 % and 0.4 %, respectively. No other valve-related complications
were observed.
Conclusions: The Bicarbon prosthetic heart valve has shown excellent clinical results and is associated with a low
incidence of valve-related complications.
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Heart valve surgeryBackground
Many types of tissue and mechanical heart valve prostheses
are commercially available worldwide. Lifelong anticoagu-
lant therapy is inevitable for patients with mechanical pros-
thetic valves, and those with tissue valves have higher risks
of structural valve dysfunction than those with mech-
anical ones. The purpose of this study was to evaluate
retrospectively the clinical performance of the Bicarbon* Correspondence: tcvmisa@jichi.ac.jp
Division of Cardiovascular Surgery, Department of Surgery, Jichi Medical
University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
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any medium, provided the original work is pr
(http://creativecommons.org/publicdomain/zevalve (Sorin Biomedica Cardio, Saluggia, Italy) implanted
at our center in Japan.Methods
This retrospective follow-up study has been approved
by Bioethics Committee of Jichi Medical University
(approval number: A12-116). Between January 1997 and
December 2011, 415 patients have been implanted with
496 Bicarbon valves at our hospital. For this study, nine of
these patients were excluded because they had previously
received another type of valve in addition to the Bicarbon.
A total of 179 patients underwent aortic valve replacementrticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 2 Etiology of valve diseases
Etiology aortic valve (cases) mmitral valve (cases)
aortic dissection 6 0
calcific stenosis 54 4
congenital malformation 28 4
infective endocarditis 22 29
ischemic disease 0 15
myxomatous degeneration 75 72
prosthetic valve dysfunction 3 9
rheumatic disease 63 87
others 7 4
Table 3 Distribution of implanted valve sizes
1) Aortic position
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aortic and mitral valve replacement (DVR). There were
230 men and 176 women of mean age 60.7 ± 11.7 years,
most of whom were older than 60 years (Table 1; 162
patients in the 7th decade, 100 in the 6th, and 79 in
the 8th). Valve re-replacement surgery was performed
in 18 patients (3.7 %). Rheumatic disease was the
most frequent cause of valve disease, followed by
myxomatous degeneration, calcific aortic stenosis, and
endocarditis (Table 2). The range of implanted valves
is shown in Table 3. There was frequent use of sizes
19, 21, and 23 in AVR, and sizes 27 and 29 in MVR.
In DVR cases, size 19 slimline and size 21 fitline valves
were mainly implanted at the aortic position. Concomitant
procedures were shown in Table 4. Tricuspid valve
annuloplasty, coronary artery bypass grafting, and replace-
ment of the ascending aortic surgery including aortic root
replacement are major concomitant interventions.
The mid-term results of 105 patients with a Bicarbon
valve as of the end of January 2000 and the prospective
follow-up study of the same patients at the end of
December 2005 have already been reported [1, 2].
Clinical data from additional patients was evaluated
on the basis of mortality and morbidity analysis.
Operative procedures and postoperative management
have been described in the previous study [1]. The inter-
national normalization ratio (INR) was controlled to
maintain values between 1.8 and 3.3 for patients having
MVR and DVR, and was between 1.3 and 1.8 for AVR
patients before 2000. Since then, the INR has been between
1.8 and 3.0 for all patients. Postoperative anticoagulation
therapy did not differ with regard to rhythm status. An
antiplatelet agent such as dipyridamole or aspirin was
added to the anticoagulation therapy.
As of the end of June 2012, 406 patients participated
in the follow-up study through an office interview,
personal phone call, or information from patients’
family physicians. Seventeen patients were lost to follow-up
(95.8 % completeness of follow-up) with a mean follow-up
of 6.6 ± 4.2 years overall (AVR, 6.8 ± 4.2 years; MVR,Table 1 Age distribution
Age classes Overall (cases) AVR (cases) MVR (cases) DVR (cases)
20 yrs≧ 2 1 1 0
21–30 yrs 9 6 2 1
31–40 yrs 17 10 5 2
41–50 yrs 33 13 13 7
51–60 yrs 100 38 44 18
61–70 yrs 162 74 60 28
71–80 yrs 79 34 23 22
81–90 yrs 4 3 1 0
AVR aortic valve replacement, MVR mitral valve replacement, DVR aortic and
mitral valve replacement, yrs years6.7 ± 4.4 years; DVR, 5.7 ± 3.4 years) and a cumulative
follow-up of 2661 patient-years (1214, 1001, and 446
patient-years for AVR, MVR, and DVR, respectively).
Statistical analyses
Analyses were performed overall on the implanted
population and stratified according to implant site
(aortic, mitral, and both aortic and mitral). Morbidity
analysis included all cardiovascular complications as
defined by Edmunds et al. [3]. Mortality data (cumulative
survival) and incidence of clinical adverse events (freedom
from events) were analyzed using the Kaplan-Meier
actuarial method and 95 % confidence interval (CI))
by implant site.
Valve-related complications included thrombosis,
embolism, anticoagulant-related bleeding, endocarditis,
and valve dysfunction, and are presented as linearized
rates. For each linearized rate, upper confidence limits
(95 % CI) are provided, according to the method reported
by Grunkemeier and Anderson [4]. For continuous
variables, descriptive statistics (mean, standard deviation,
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aortic surgery 41 38 2 1
coronary artery bypass grafting 51 24 19 8
maze procedure 28 2 15 11
tricuspid valve annuloplasty 58 4 35 19
others 14 10 2 2
AVR aortic valve replacement, MVR mitral valve replacement, DVR aortic and
mitral valve replacement
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performed using StatView v.5 (SAS Institute Inc., Cary,
NC, USA).
Results
Survival and clinical functional class
Ninety-nine patients died, including 10 hospital deaths
(6 low cardiac output syndromes, 1 non-obstructive
mesenteric infarction, 1 sepsis, 1 arrhythmia, and 1 aor-
tic rupture). Late mortality consisted of 17 heart failures,
11 renal failures, 11 malignancies, 9 sudden deaths, 7 cere-
bral hemorrhages (including 4 subarachnoidal hemor-
rhages), 9 respiratory failures, 6 cerebral infarctions, 6
hepatic failures, 3 myocardial infarctions, 3 accidents, and
7 for other reasons. Survival rates at 6 years were 80.1 %
(95 % CI: 75.9–84.5 %) overall, 82.6 % (76.6–89.0 %) for
AVR, 78.8 % (71.9–86.3 %) for MVR, and 77.1 %
(67.1–88.6 %) for DVR, and those at 12 years 64.2 %
(57.6–71.6 %), 67.1 % (57.3–78.5 %), 63.1 % (52.8–75.4 %),
and 61.0 % (47.3–78.6 %), respectively (Fig. 1).
Valve-related death occurred in 9 patients in the AVR
group, 10 in the MVR group, and 3 in the DVR group.
Rates of freedom from valve-related death at 6 years
were 95.4 % (93.2–97.8 %) overall, 95.7 % (92.4–99.2 %)
for AVR, 94.8 % (90.8–99.0 %) for MVR, and 96.1 %Fig. 1 Survival from all death. Numerical values of the graph express numb
including AVR, MVR, and DVR cases; AVR: aortic valve replacement cases, M
replacement cases(91.9–100.00 %) for DVR, and those at 12 years
89.4 % (84.3–94.9 %), 92.7 % (87.6–98.1 %), 84.3 %
(74.2 − +95.7 %), and 96.1 % (91.9–100.00 %), respectively
(Fig. 2). Valve-related death included 10 sudden death
cases. Rates of freedom from sudden death at 6 years were
98.0 % (96.4–99.5 %) overall, 97.3 % (94.7–100.0 %) for
AVR, 97.7 % (95.0–100.0 %) for MVR, and 100 % for
DVR, and those at 12 years 95.7 % (92.1–99.4 %),
95.9 % (92.1–99.8 %), 93.9 % (86.6–100.0 %), and 100 %,
respectively (Fig. 3)
Preoperatively, 66.6 % of the patients were in the New
York Heart Association (NYHA) functional class III or
IV, and 95.0 % of the surviving patients were in class I
or II at follow-up.
Valve-related complications
Forty-five valve-related complications were observed in
the whole group, including 13 bleeding complications,
12 thromboembolisms, 5 endocarditis, and 5 paravalvular
leakages without endocarditis. Ten patients with prosthetic
valve endocarditis, paravalvular leakage or prosthetic valve
thrombosis underwent reoperation. Rates of freedom from
all valve-related complications at 6 years were 92.5 %
(89.7–95.3 %) overall, 92.3 % (88.2–96.6 %) for AVR,
92.2 % (87.7–97.0 %) for MVR, and 93.4 % (87.9–99.2 %)
for DVR, and at those at 12 years 81.1 % (75.0–87.8 %),
82.7 % (75.2–91.1 %), 79.3 % (68.6–91.7 %), and 81.6 %
(67.0–99.4 %), respectively (Fig. 4).
Rates of freedom from thromboembolism at 6 years
were 97.4 % (95.7–99.1 %) overall, 97.2 % (94.5–100.0 %)
for AVR, 97.7 % (95.2–100.0 %) for MVR, and 97.4 %
(93.8–100.0 %) for DVR, and those at 12 years 95.4 %
(92.7–98.3 %), 94.6 % (90.2–99.2 %), 95.9 % (91.8–100.0 %),
and 97.4 % (93.8–100.0 %), respectively (Fig. 5). Freedom
from prosthetic valve endocarditis at 12 years was 97.3 %
(94.4–100.0 %) overall, 99.4 % (98.3–100.0 %) for AVR,ers of patients at the time of follow-up. Abbreviations; All: all cases
VR: mitral valve replacement cases; DVR: both aortic and mitral valve
Fig. 2 Survival from valve related death. Abbreviations; All: all cases including AVR, MVR, and DVR cases; AVR: aortic valve replacement cases,
MVR: mitral valve replacement cases; DVR: both aortic and mitral valve replacement cases
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for DVR (Fig. 6). Freedom from non-structural para-
valvular leakages at 12 years was 98.9 % (97.9–100.0 %)
overall, 98.8 % (97.2–100.0 %) for AVR, 98.5 % (96.5–
100.0 %) for MVR, and 100 % for DVR (Fig. 7). Rates
of freedom from hemorrhagic complications at 6 years
were 98.0 % (96.5–99.5 %) overall, 98.1 % (96.0–100.0 %)
for AVR, 98.2 % (95.7–100.0 %) for MVR, and 97.4 %
(94.0–100.0 %) for DVR, and those at 12 years 92.5 %
(88.0–97.3 %), 93.5 % (88.1–99.2 %), 92.4 % (84.65–
100.0 %), and 90.5 % (77.9–100.0 %), respectively (Fig. 8).
Rates of freedom from reoperation at 6 years were 98.0 %
(96.6–99.5 %) overall, 98.2 % (96.3–100.0 %) for AVR,
97.6 % (94.9–100.0 %) for MVR, and 98.5 % (95.6–100.0 %)
for DVR, and those at 12 years 96.1 % (93.1–99.3 %),
98.2 % (96.3–100.0 %), 94.4 % (88.1–100.0 %), and
93.0 % (82.8–100.0 %), respectively (Fig. 9). We experi-
enced no structural prosthetic valve dysfunction.Fig. 3 Freedom from sudden death. Abbreviations; All: all cases including A
mitral valve replacement cases; DVR: both aortic and mitral valve replacemLinearized rates and upper confidence limits of events
The linearized rates and 95 % CI of each event overall were
0.5 % (0.3–0.9 %) per patient-year for thromboembolic
events, 0.5 % (0.3–0.9 %) per patient-year for bleeding,
0.2 % (0.1–0.4 %) per patient-year for prosthetic
endocarditis, 0.2 % (0.1–0.4 %) per patient-year for
paravalvular leak, 0.4 % (0.2–0.7 %) per patient-year for
sudden death, and 1.4 % (0.8–2.5 %) per patient-year for
all valve-related complications.
Linearized rates of the AVR group were 0.5 % (95 %
CI: 0.2–1.0 %) per patient-year for thromboembolic
events, 0.5 % (0.2–1.0 %) per patient-year for bleeding,
and 1.6 % (1.1–2.7 %) per patient-year for all valve-related
complications. Those of the MVR group were 0.4 %
(0.1–1.0 %) for thromboembolic events, 0.4 % (0.1–1.0 %)
for bleeding, and 1.6 % (0.8–3.2 %) for all valve-related
complications. Those of the DVR group were 0.5 %
(0.1–1.6 %) for thromboembolic events, 0.7 % (0.2–1.9 %)VR, MVR, and DVR cases; AVR: aortic valve replacement cases, MVR:
ent cases
Fig. 4 Freedom from all valve related complications. Abbreviations; All: all cases including AVR, MVR, and DVR cases; AVR: aortic valve
replacement cases, MVR: mitral valve replacement cases; DVR: both aortic and mitral valve replacement cases
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complications.
Discussion
Tissue valves are more likely than mechanical valves to be
implanted in Japan, with 11,656 tissue and 5050 mechanical
heart valves implanted in 2012 [5]. Prolonged durability of
the tissue valves, an aging population, and an increasing
number of plastic surgery techniques have led to a decrease
in the use of mechanical valves. Nevertheless, mechanical
valves appear to be a better option for some patients. At
our institution we choose a mechanical valve for young
adults and patients with end-stage renal disease because of
the rapid structural dysfunction of tissue valves [6].
Excellent early and mid-term clinical results of the
Bicarbon valve have been previously reported [1, 7–11].
We also reported early and mid-term results with theFig. 5 Freedom from thromboembolism. Abbreviations; All: all cases includ
MVR: mitral valve replacement cases; DVR: both aortic and mitral valve replprosthetic valve in 2002 and 2007. Only long-term
follow-up studies, however, will be sufficient enough
to properly evaluate its clinical performance. Here we
report our 15-year clinical experience with the Bicarbon
valve.
With regard to single-center mid-term results, Goldsmith
and colleagues reported in 1998 that the Bicarbon valve has
a satisfactory clinical performance with low complication
rates [7]. A 2004 multicenter study of the Bicarbon valve in
Europe with a mean follow-up of 2.2 ± 1.5 years showed
rates of 5 % early death and 4.4 % late death [8]. In
addition, the linearized incidence of valve thrombosis
was between 0.06 % and 0.69 % per patient-year
among the AVR, MVR, and DVR groups, and that of
embolic episodes was between 1.13 % and 2.14 % per
patient-year. Bleeding complications occurred at a rate
of 0.69–1.26 % per patient-year.ing AVR, MVR, and DVR cases; AVR: aortic valve replacement cases,
acement cases
Fig. 6 Freedom from prosthetic valve endocarditis. Abbreviations; All: all cases including AVR, MVR, and DVR cases; AVR: aortic valve replacement
cases, MVR: mitral valve replacement cases; DVR: both aortic and mitral valve replacement cases
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thrombosis at 7–9 years was between 97 % and 99.4 %,
freedom from embolic episodes was between 64 %
and 93 %, and freedom from bleeding complications
was between 82 % and 98.6 % [9–11]. Actuarial analysis at
7–9 years showed an overall survival of between 63.9 %
and 88 %.
Regarding long-term multicenter clinical results,
Azarnoush and colleagues reported actuarial survival
at 15 years of 61.4 % for AVR, 63.4 % for MVR, and
56.4 % for DVR [12]. They added that actuarial freedom
from thromboembolism, anticoagulant-related hemorrhage,
and endocarditis at 15 years was 88.8 %, 77.5 %, and 96.8 %,
respectively, without any cases of structural failure of the
prosthesis.
Long-term clinical experience with the St. Jude Medical
and Carbomedics bileaflet mechanical valves for AVR and
MVR have shown rates of thrombosis of between 0.73 %
and 3.4 % per patient-year, and 10-year freedom from
thrombosis of between 77 % and 94.2 % [12–21]. InFig. 7 Freedom from paravalvular leakage. Abbreviations; All: all cases inclu
MVR: mitral valve replacement cases; DVR: both aortic and mitral valve repladdition, the rates of bleeding were between 0.52 % and
2.7 % per patient-year, and the 10-year freedom from
bleeding ranged from 77 % to 96.4 %. Our previous
reports concluded that the results obtained were simi-
lar to those for other mechanical valves associated
with a low incidence of valve-related morbidity and
mortality [1, 2].
Jeong and colleagues reported long-term clinical results
with the ATS mechanical valve in 1382 consecutive
patients, revealing that the survival rates at 12 years
were 87.0 ± 3.8 % in the AVR group and 71.4 ± 6.3 %
in the DVR group [22]. In addition, there was a higher
cardiovascular event-free survival at 12 years in the
AVR group than the DVR group (82.3 ± 4.7 % versus
65.1 ± 7.3 %). Another long-term study was conducted
by Sezai, who reported bleeding events at a rate of 0.19 %
and thromboembolic events of 0.44 % per patient-year in
231 cases over 15 years of observation [22].
In the present era, a bileaflet valve is more likely than
a tilting disc valve to be implanted. In 2001 we revealedding AVR, MVR, and DVR cases; AVR: aortic valve replacement cases,
acement cases
Fig. 8 Freedom from hemorrhagic complications. Abbreviations; All: all cases including AVR, MVR, and DVR cases; AVR: aortic valve replacement
cases, MVR: mitral valve replacement cases; DVR: both aortic and mitral valve replacement cases
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valve in 168 consecutive patients of mean age 53 years
[23]. Freedom from thromboembolism at 10 years was
94 % in the AVR group, 80 % in the MVR group, and 96 %
in the DVR group, and that from hemorrhagic com-
plications was 86 %, 92 %, and 100 %, respectively.
The Ominicarbon valve showed good clinical perfor-
mances similar to the Bicarbon valve. The increasing
age of patients with a narrow aortic valve annulus
and posterior leaflet preservation techniques in MVR
have led us to choose bileaflet mechanical valves [24].
However, one must be aware of the possible risk of the
valve becoming stuck because of the posterior orientation
of the major orifice.
Although structural dysfunction has been overcome,
valve-related complications after heart valve replacement
with mechanical valves occur at unacceptable rates.
Thromboembolic and hemorrhagic events related to anti-
coagulant therapy should be considered during lifelong
follow-up. Non-structural prosthetic valve dysfunctionsFig. 9 Freedom from reoperation. Abbreviations; All: all cases including AV
valve replacement cases; DVR: both aortic and mitral valve replacement cassuch as paravalvular leak and pannus ingrowth are
also issues to be resolved [25].
The present study gives additional evidence of low
rates of valve-related complications after Bicarbon valve
implantation. Our anticoagulation therapy is associated
with an antiplatelet agent. Patients with INR >3.0
sometimes develop lethal bleeding complications, so we
maintain the INR between 1.8 and 3.0. The rate of
thromboembolic events in this study is excellent and the
rates of bleeding complications are also acceptable. We
confirm that anticoagulation for patients with a mechanical
valve should be implemented in association with an anti-
platelet agent. Postoperative NYHA functional improve-
ment was satisfactory in all groups. Low cardiac output
syndrome led to lethal complications in those patients with
advanced stage IV NYHA classification. To obtain better
clinical outcomes, an operation before advanced functional
class is reached should be considered, and more intensive
perioperative management may be mandatory for patients
with heart failure that is far advanced.R, MVR, and DVR cases; AVR: aortic valve replacement cases, MVR: mitral
es
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Many patients have been followed by their family
physicians for several months after surgery for reasons of
patients’ convenience. Some visit our outpatient clinic
once or twice a year, while others do not. We sometimes
experience poorly controlled anticoagulant therapy among
such patients, which might lead to thromboembolic and
bleeding complications. Unfortunately, we were unable
to evaluate the INR of some patients suffering from
thromboembolic and/or bleeding events. In addition,
deaths from unknown causes are included in the category
of sudden death, meaning that the rate of cases of sudden
death may be higher than its true incidence.
Conclusions
This single-center study of a 15-year follow-up of the
Bicarbon prosthetic heart valve shows excellent clinical
results associated with a low incidence of valve-related
mortality and morbidity.
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